MAIA Biotechnology Inc (MAIA)

개요 뉴스 가격 이력 토론 예측

MAIA Biotechnology Inc 주식(MAIA)의 최신 뉴스

MAIA Biotechnology Inc (MAIA)

MAIA Biotechnology Inc 주식(MAIA)의 최신 뉴스

MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting - Business Wire

MAIA Biotechnology Announces Director Participation in Recent Private Placement - Business Wire

Best Momentum Stocks to Buy for May 6th - The Globe and Mail

MAIA Biotechnology Raises $1.08M in Private Placement - TipRanks

MAIA Biotechnology launches $1.08M private placement - MSN

CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement - Business Wire

MAIA Biotechnology secures $1.08 million in private placement By Investing.com - Investing.com Canada

Maia Biotechnology Announces $1.08 Million Private Placement - marketscreener.com

MAIA Biotechnology secures $1.08 million in private placement - Investing.com

MAIA Biotechnology Raises $1.08M at $1.50 Per Share to Advance Phase II Cancer Trial - Stock Titan

MAIA Biotechnology Announces $1.08 Million Private Placement - Business Wire

MAIA Biotechnology Inc (MAIA) Stock: A 52-Week Tale of Drops and Gains - investchronicle.com

Do investors need to be concerned about MAIA Biotechnology Inc (MAIA)? - uspostnews.com

MAIA Biotechnology Inc: Navigating Market Fluctuations with a 60.66M Market Cap - investchronicle.com

MAIA Biotechnology Inc [MAIA] stock for 50,000 USD was acquired by Guerrero Ramiro - knoxdaily.com

MAIA’s Q2 earnings predictions: What the experts say - uspostnews.com

MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading Up 14.8% – Here’s Why - Defense World

MAIA Biotechnology publishes preclinical data for telomere-targeting THIO dimer - MSN

MAIA stock touches 52-week low at $1.41 amid market challenges - Investing.com India

MAIA Biotechnology- Phase 2 Trial Thio-101 Expansion Underway Potential Filing In 2026 For Accelerated Approval - MarketScreener

MAIA Biotechnology targets 2026 for FDA approval of cancer drug - Investing.com

Breakthrough Cancer Drug Pipeline: MAIA's Telomere-Targeting Therapy Eyes FDA Fast Track - Stock Titan

MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders - BioSpace

MAIA Biotechnology, Inc. (MAIA) Upgraded to Buy: Here's What You Should Know - MSN

Is MAIA Biotechnology, Inc. (MAIA)he Cheapest Stock Insiders Are Buying In March? - Insider Monkey

MAIA Biotechnology Showcases THIO-101 Trial at ELCC 2025 - TipRanks

Q1 EPS Forecast for MAIA Biotechnology Lifted by Analyst - Defense World

MAIA Biotechnology revises offering to $11.2 million By Investing.com - Investing.com Australia

Diamond Equity Comments on MAIA Biotechnology Q1 Earnings - Defense World

MAIA Biotechnology revises offering to $11.2 million - Investing.com

Maia Biotechnology IncDecreases Maximum Aggregate Offering Price To $11.2 MillionSEC Filing - Marketscreener.com

15 Cheapest Stocks Insiders Are Buying In March - Insider Monkey

MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025 - BioSpace

Breakthrough Lung Cancer Drug Shows Exceptional Phase 2 Results: Key Biomarker Discovery - Stock Titan

Maia Bio touts two advances for its lead cancer drug in development - Crain's Chicago Business

MAIA Biotechnology reports breakthrough in cancer treatment research By Investing.com - Investing.com South Africa

MAIA Biotechnology advances with new drug name approval By Investing.com - Investing.com Australia

MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug - BioSpace

MAIA Biotechnology reports breakthrough in cancer treatment research - Investing.com

MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO - BioSpace

Maia Biotechnology Receives Usan Council Approval For "Ateganosine" As Nonproprietary Name For Anticancer Agent Thio - Marketscreener.com

MAIA Biotechnology advances with new drug name approval - Investing.com

MAIA Biotechnology receives USAN Council approval for ‘Ateganosine’ name - TipRanks

MAIA Biotechnology, Inc. Receives USAN Council Approval for "Ateganosine" as Nonproprietary Name for Anticancer Agent THIO - Marketscreener.com

MAIA과 유사한 종목